ZYME Maintains Buy Rating by Citigroup -- Price Target Raised to $38

gurufocus.com · 2026-08-26

Zymeworks (ZYME) Analyst Rating Update - September 28, 2023 On September 28, 2023, Citigroup maintained a Buy rating on Zymeworks (ZYME), raising the price t

TickrTrends take: Citigroup's maintained buy rating and raised price target of $38 for ZYME suggests analyst confidence in the company's prospects, though TickrTrends is currently awaiting full valuation data on the Healthcare sector company. For valuation-focused investors, the divergence between Citigroup's $38 target and ZYME's current trading price would be a key metric to monitor as additional valuation metrics become available through TickrTrends. The timing of this analyst action may provide useful context once comprehensive valuation analysis is complete.

Read the full story at gurufocus.com →